Your SlideShare is downloading. ×
0
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Innovation in drug development processes - CDE themed call launch 25 June 2013
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Innovation in drug development processes - CDE themed call launch 25 June 2013

526

Published on

Presentation slides from CDE themed call launch event on 25 June - for full details of this call see: http://www.science.mod.uk/events/event_detail.aspx?eventid=259

Presentation slides from CDE themed call launch event on 25 June - for full details of this call see: http://www.science.mod.uk/events/event_detail.aspx?eventid=259

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
526
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
14
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Innovation in DrugDevelopment ProcessesCentre for Defence Enterprise
  • 2. Rapid technological change
  • 3. © Crown Copyright MOD 2011The aim of CDE
  • 4. © Crown Copyright MOD 2011Prove the value of novel, high-risk,high-potential-benefit research
  • 5. © Crown Copyright MOD 2011Cost-effective militarycapability advantage
  • 6. 25 June 2013Five key operating principlesunderpin the CDE model
  • 7. Engaging innovators
  • 8. 25 June 2013Accessible opportunity
  • 9. Sustaining incentives
  • 10. Minimising participation costs
  • 11. Compliance
  • 12. Two routes to funding
  • 13. Online bid submission
  • 14. Intellectual property
  • 15. Themed calls
  • 16. CDE themed call programmeCountering insider threat attacks Call closes 27 Jun 2013Secure communications Call closes 22 Aug 2013Innovation in drug developmentprocessesCall closes 29 Aug 2013Enhancing military medical trainingand support for the medicCall launch 16 July 2013(Birmingham)Novel solutions for emulating shipsignatures (countermine)Call launch 23 July 2013(Webinar)Register and further details at www.science.mod.uk under ‘Events and Calls’All call close at 17:00 hrs
  • 17. Defence Open Call
  • 18. Seeking the exceptional
  • 19. Challenging conventions
  • 20. 4419proposals received
  • 21. 17%proposals funded
  • 22. £39Mcontracts awarded
  • 23. Exemplar project
  • 24. Fuel efficiency
  • 25. ‘Micro generators’
  • 26. © Crown Copyright MOD 2011Effective proposals
  • 27. Challenge, pace & exploitation
  • 28. The future of CDE
  • 29. Network and question
  • 30. Centre for Defence Enterprise01235 438445cde@dstl.gov.ukwww.science.mod.uk/enterprise
  • 31. © Crown copyright 2013 Dstl25 June 2013
  • 32. An Introduction to CBR Science andTechnologyUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 33. Chemical, Biological, RadiologicalVISIONMaximise the impact of science and technology (S&T) inrealising the UK policy aim of maintaining our political andmilitary freedom of action despite the presence, threat, or useof chemical, biological or radiological weapons.SDSR: NATIONAL SECURITY TASKS & PLANNINGGUIDELINES:We will .. tackle those who threaten the UK & our interests,including maintenance of underpinning technical expertise in keyareas. To deliver this we require …Retention of our CBRN science and technology capabilities thatcontribute to counter-proliferation and our response to thepotential use of such materials by terrorist or state actors.NATIONAL SECURITY STRATEGY: RISKSTier 1 : International terrorism including the use of CBRNmaterialsTier 2 : Attack on the UK or its Territories by a state or proxyusing CBRN weapons.UNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 34. • Strategic objectives– SUPPORT 3 Model Block (MB)acquisitions• More tech watch type activity. Lessdevelopment activity in researchprogramme– INCREASE the amount of speculative,high-risk, high-reward research.• Emphasis on scientific quality andinnovation.• Pause mature research25 June 2013Context© Crown copyright 2013 DstlF12/13 F13/14Threat 6.4M 6.1MInform 7.9M 7.1MProt Measures 14.9M 14.2MStratFacilities 6.2M 6.4M£35.4M £33.8MCBR research programme fundingUNCLASSIFIED
  • 35. SenseKnowledgeManagementPhysicalHazardManagementMedicalCountermeasuresHazardAssessmentOperationalAnalysisCounterProliferationDutyOf CareCBR Inform(MOD & Industry)CBR Protective Measures(InternationalCollaboration)CBR Threat Reduction(Cross Government)CBR S&TProgrammePreventionof SupplyProtectionEliminationArmsControlDisablementDeterrenceProgramme structureUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 36. Programme and Delivery DirectorateCBR programmeOtherprogrammesDstl DeptsIndustry AcademiaS&T RequirementsPartnersUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 37. Working across government• Aim: programme coherency and mutualbenefit from shared investments• Number of other government departments withinterest/requirement for CBRN S&T advice• Different exploitation routes, similar fundamentalrequirementsUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 38. Impact of S&TUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 39. Exploitation of S&T and where industry isinvolvedEarly InnovationProof of conceptAssessmentTech transfer Into serviceUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 40. Alternative modelN2SampleInlet to DetectorCapabilityResearch exploitationNon-MOD marketsRapidAdaptationUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 41. CBRN PROTECTION RESEARCH GOAL 9 –Medical Countermeasures• Explore technology optionstoupkeep, updateand upgrade the CBRNmedical countermeasures capability.• To prevent individualsfromexperiencing the physiological effectsof exposure to CBRN agents by the useof medical countermeasures, in orderto maintainoperationaleffectivenesson operations.• To move towards a post-exposuretreatment posture while maintainingthe current pre-exposure capability.UNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 42. Desired outcome: Strategic approach• Where practicable all future medicalcountermeasures (MedCM) should belicensed (ie possess a MarketingAuthorisation in the UK).• Broad-spectrum MedCM: provide protectionagainst more than one agent.25 June 2013UNCLASSIFIED© Crown copyright 2013Dstl
  • 43. Programme aim• MOD long-term aim: broad-spectrumpost-exposure therapies• Allow a flexible response to currentand emerging threatsUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 44. BW MedCM strategyPre-exposure therapies• Devise vaccines against biological agentsPost-exposure therapies• BW-specific post-exposure therapies• Broad-spectrum therapiesLessens the need to pre-define the threatspectrumDelivery is dependent on collaborationRisk30%70%UNCLASSIFIED25 June 2013© Crown copyright 2013Dstl
  • 45. A technical challenge• The challenge of devising broad-spectrum MedCM issignificant– very challenging technical aspiration• Incentivising industry to engage with MOD is difficult in thisarea• Few incentives to develop broad-spectrum therapies– Profit is in specific therapies for chronic diseases• Low investment means there are very few broad-spectrumantibiotics in the pipelineUNCLASSIFIED© Crown copyright 2013Dstl25 June 2013
  • 46. Summary• The CBR research programme is designed to maximise theimpact of science & technology in realising the UK policy aim ofmaintaining our political and military freedom of action despitethe presence, threat, or use of chemical, biological or radiologicalweapons.• Broad-spectrum medical countermeasures are mechanism toachieve this• This CDE themed call is aimed to help identify future medicalcountermeasures25 June 2013UNCLASSIFIED© Crown copyright 2013Dstl
  • 47. CDE Themed Call:Innovation in Drug DevelopmentProcesses© Crown copyright 2013 Dstl25 June 2013UNCLASSIFIED
  • 48. CDE call:Innovation in Drug Development ProcessesAims to stimulate the development of antibacterial drugdevelopment processes…• benefiting the antibacterial development industry• supporting the UK’s defence and security needsUNCLASSIFIED25 June 2013© Crown copyright 2013Dstl
  • 49. • Research proposals for this CDE themed call will alsobe assessed by representatives from Dstl’scollaborators in US Government, the Defence ThreatReduction Agency (DTRA) and a selection of UKbased University academics.• The US/academia will not be funding any of theproposals resulting from this CDE call – funding willonly be from Dstl.© Crown copyright 2013 Dstl25 June 2013CDE call:Innovation in Drug Development ProcessesUNCLASSIFIED
  • 50. © Crown copyright 2013 Dstl25 June 2013
  • 51. Innovations in DrugDevelopment Processes25 June 2013© Crown copyright 2013 DstlUNCLASSIFIED
  • 52. Overview• Background: target identification at Dstl• CDE call: improving target exploitationUNCLASSIFIED25 June 2013© Crown copyright 2013 Dstl
  • 53. 25 June 2013© Crown copyright 2013 DstlBroad-spectrum antibacterialsIn order to support the development of novel antibioticsby industry, MOD funds research to identify and validatebroad-spectrum antibacterial targetsBacillusanthracisBurkholderiapseudomallei /malleiYersiniapestisFrancisellatularensisCoxiellaburnetiiBrucella sppUNCLASSIFIED
  • 54. Dstl’s key capabilities25 June 2013Animal modelsGenetic manipulation ofpathogensIn vitro modelsof infectionCytoplasmicmembraneCellwallCapsuleUNCLASSIFIED© Crown copyright 2013Dstl
  • 55. 25 June 2013• Target selectionIdentification• Biological evaluation of target• Down-selectionCharacterisation andvalidation• Collaborations• Evaluation of novel technologies forinhibitor selectionExploitationApproach to antibacterial targetsUNCLASSIFIED© Crown copyright 2013Dstl
  • 56. Target identification• Whole genome approaches– Using high-throughput sequencingtechnology• Bioinformatics– Database of Essential Genes– Pathogen vs non-pathogens• Computational systemsbiology– Mathematical modelling25 June 2013UNCLASSIFIED© Crown copyright 2013Dstl
  • 57. Target characterisation and validation• Genetic characterisation– Development and construction of targeted mutants– In vitro & in vivo evaluation• Virulence• Essential• Biochemical characterisation– Protein engineering– X-ray crystallography25 June 2013UNCLASSIFIED© Crown copyright 2013Dstl
  • 58. Target exploitation• Engagement with academia and/or industryCurrently:– Target protein structures– Assay development– Inhibitor screening (proof-of-concept)Future:– Inhibitor screening & lead moleculedevelopment25 June 2013UNCLASSIFIED© Crown copyright 2013Dstl
  • 59. 25 June 2013Aspiration– Enable development of broad-spectrumantibacterials– Engage with academic/industrial partners at anearly stageUNCLASSIFIED© Crown copyright 2013Dstl
  • 60. 25 June 2013CDE callInnovation in Drug Development ProcessesAims to stimulate the development of antibacterial drugdevelopment processes…• benefiting the antibacterial development industry• supporting the UK’s defence and security needsUNCLASSIFIED© Crown copyright 2013Dstl
  • 61. Target-based antibacterial discovery25 June 2013Target identificationHigh throughputscreening or alternativeapproachInhibitor identificationLead inhibitor optimisation(PK, distribution, toxicity, etc)Structure-based drugdesignUNCLASSIFIED© Crown copyright 2013Dstl
  • 62. 25 June 2013Challenge 1: Specific target inhibitoridentification• eg– decreasing propensity for resistance acquisition– increasing hit rateTechnologies that improve the robustness ofinhibitors identified for targets by HTS or otherapproachesUNCLASSIFIED© Crown copyright 2013Dstl
  • 63. 25 June 2013Challenge 2: Improving structure-based drug design• eg– reducing the time taken to produce high-resolutiontarget structures– increasing robustness of in silico small moleculedesignTechnologies that improve the process of structure-based drug design of antibacterialsUNCLASSIFIED© Crown copyright 2013Dstl
  • 64. 25 June 2013Challenge 3: Potency for intracellularpathogens• eg– altering physiochemical properties of inhibitors toenhance uptake– coupling inhibitors to other molecules to increaseintracellular retentionTechnologies that improve the uptake of antibacterialsinto target cells and/or reduce effluxUNCLASSIFIED© Crown copyright 2013Dstl
  • 65. 25 June 2013What we WANT• Proof-of-concept proposals• Highly innovative approaches, tools, technologies• Applicability to broad-spectrum targets• Applicability to intracellular bacteriaUNCLASSIFIED© Crown copyright 2013Dstl
  • 66. 25 June 2013What we DONT WANT• Existing technologies• Target identification• Target-specific approachesUNCLASSIFIED© Crown copyright 2013Dstl
  • 67. 25 June 2013Proposals• Proof of concept• Value: no cap but likely £20-80K• Duration: typically 3-9 months; to be completed by September2014• Call closes: 29 August 2013 at 1700 hrs• Contract placement to be initiated from October 2013UNCLASSIFIED© Crown copyright 2013Dstl
  • 68. 25 June 2013Enquiries• Technical enquiries: cbrcde@dstl.gov.uk• General enquiries: cde@dstl.gov.uk+44 (0)1235 438445UNCLASSIFIED© Crown copyright 2013Dstl
  • 69. © Crown copyright 2013 Dstl25 June 2013
  • 70. Crown Copyright (c) 2012Centre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukUNCLASSIFIED / FOR PUBLIC RELEASECentre for Defence EnterpriseSubmitting a Successful ProposalCentre for Defence Enterprise (CDE)
  • 71. Maximising your chances
  • 72. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012Know what is available
  • 73. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012Know what is available
  • 74. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012Know what is available
  • 75. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012Read availableinformationStart with –Quick Start Guideplus other CDE manuals –Account Manual, UserManual, TechnologyApplication ManualKnow what is available
  • 76. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012Know what is available
  • 77. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012Developing a CDE proposal
  • 78. Dstl is part of theMinistry of DefenceValue from technologyInnovativeconceptFuturecapabilityProofofconcept Incremental development
  • 79. The essentials
  • 80. Description
  • 81. minsAssessment
  • 82. Not an exam
  • 83. MOD Performance Assessment FrameworkFive criteria:Operational relevanceLikelihood of exploitationBuilds critical S&T capability to meet UKneedsScientific quality/innovationScience, innovation and technology risk
  • 84. Commercial tab
  • 85. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012Government-furnished X
  • 86. Health and safety
  • 87. Ethics
  • 88. Unclassified
  • 89. Crown Copyright (c) 2012Centre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukUNCLASSIFIED / FOR PUBLIC RELEASEProposal health check
  • 90. Claim of future benefit
  • 91. Contribution to future benefit
  • 92. Logical programme of work
  • 93. Generation of evidence
  • 94. Demonstration of progress
  • 95. Crown Copyright (c) 2012Centre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukUNCLASSIFIED / FOR PUBLIC RELEASEBased on a claim of future benefitContribution to realisation of future benefitLogical programme of workEvidential outcomesDemonstration of progress towards goalHealth check
  • 96. Early birds
  • 97. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012This call closes:17:00 hrs onThursday 29 August 2013Deadline
  • 98. Crown Copyright (c) 2012Centre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukUNCLASSIFIED / FOR PUBLIC RELEASECentre for Defence Enterprisecde@dstl.gov.ukwww.science.mod.uk/enterpriseCall process queries
  • 99. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012cbrcde@dstl.gov.ukCall technical queries
  • 100. Dstl is part of theMinistry of DefenceUNCLASSIFIED / For Public ReleaseCentre for Defence Enterprisewww.science.mod.uk/enterprise cde@dstl.gov.ukCrown Copyright Dstl 2012www.science.mod.ukEvents and Calls > Current callsfor proposals > Innovation in drugdevelopment processesFurther information

×